LaJolla Pharmaceuticals initiates a Phase 2 clinical trial assessing LJPC-401 (synthetic human hepcidin) in patients with hereditary hemochromatosis, a deficiency of the hormone hepcidin which leads …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
